Progyny Quarterly Cash Flow Statement
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Progyny free cash flow
In the quarter ended Jun 30, 2026, Progyny generated $50.4 million of operating cash flow and spent $6.2 million on capital expenditures. That left free cash flow of $44.2 million, a free-cash-flow margin of 12.6% of revenue. Free cash flow was down 12.0% from the prior year's $50.2 million.
Progyny returned $30.0 million to shareholders through share repurchases, equal to 68% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Progyny cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 28.05M | 24.23M | 12.48M | 13.86M | 17.11M | 15.06M | 10.53M | 10.42M | 16.48M | 16.90M | 13.47M | 15.90M |
| Net Income growth (YoY) | +63.93% | +60.91% | +18.54% | +33.04% | +3.80% | -10.88% | -21.81% | -34.45% | +9.97% | -4.41% | +295.25% | +20.34% |
| Depreciation & Amortization | 1.62M | 1.48M | 1.37M | 1.27M | 1.21M | 1.11M | 868.00K | 837.00K | 754.00K | 716.00K | 634.00K | 579.00K |
| Stock-Based Compensation | 20.48M | 19.72M | 34.80M | 32.17M | 32.38M | 32.51M | 30.86M | 33.18M | 33.04M | 31.05M | 28.80M | 31.25M |
| Change in Working Capital | -11.20M | -4.54M | 31.04M | -9.45M | 12.59M | -22.50M | 26.78M | -15.08M | 6.34M | -40.16M | -5.03M | -378.00K |
| Operating Cash Flow | 50.42M | 45.95M | 54.20M | 50.67M | 55.51M | 49.81M | 52.16M | 44.52M | 56.69M | 25.73M | 37.66M | 54.18M |
| Capital Expenditures | -6.22M | -6.35M | -5.61M | -4.68M | -5.27M | -2.84M | -1.90M | -1.79M | -866.00K | -850.00K | -681.00K | -953.00K |
| Investing Cash Flow | 3.55M | 96.59M | 8.26M | -42.74M | -29.91M | -94.61M | 74.99M | 15.36M | 86.10M | 19.34M | -93.41M | -64.31M |
| Share Repurchases | -30.02M | -118.61M | -81.66M | 0 | 0 | 0 | -55.10M | -61.45M | -159.96M | -23.76M | 0 | 0 |
| Financing Cash Flow | -32.89M | -123.11M | -88.26M | -5.49M | -2.33M | -3.29M | -56.33M | -63.35M | -162.79M | -27.41M | -5.03M | -2.36M |
| Net Change in Cash | 21.03M | 19.38M | -25.79M | 2.44M | 23.30M | -48.08M | 70.83M | -3.48M | -20.00M | 17.66M | -60.78M | -12.49M |
| Free Cash Flow | 44.21M | 39.60M | 48.59M | 45.99M | 50.24M | 46.97M | 50.27M | 42.72M | 55.83M | 24.88M | 36.98M | 53.23M |
This table shows 12 quarterly periods of Progyny's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PGNY's reporting calendar. What is a cash flow statement?